ID   HSC-2
AC   CVCL_1287
SY   HSC2
DR   BTO; BTO:0003881
DR   CLO; CLO_0051383
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1284
DR   BioSample; SAMN03471637
DR   BioSample; SAMN03472038
DR   BioSample; SAMN10987832
DR   cancercelllines; CVCL_1287
DR   Cell_Model_Passport; SIDM00590
DR   CGH-DB; 358-2
DR   ChEMBL-Cells; CHEMBL3308482
DR   ChEMBL-Targets; CHEMBL1075468
DR   Cosmic; 753562
DR   Cosmic; 930330
DR   Cosmic; 932147
DR   Cosmic; 1046027
DR   Cosmic; 1118788
DR   Cosmic; 1120697
DR   Cosmic; 1123038
DR   Cosmic; 1140780
DR   Cosmic; 1219864
DR   Cosmic; 1571799
DR   Cosmic; 1530743
DR   Cosmic; 2266783
DR   Cosmic; 2546835
DR   Cosmic-CLP; 753562
DR   DepMap; ACH-000472
DR   EGA; EGAS00001000978
DR   GDSC; 753562
DR   GEO; GSM243521
DR   GEO; GSM827233
DR   GEO; GSM850382
DR   GEO; GSM887133
DR   GEO; GSM888204
DR   GEO; GSM1669903
DR   IARC_TP53; 1101
DR   JCRB; JCRB0622
DR   LiGeA; CCLE_109
DR   LINCS_LDP; LCL-1206
DR   PharmacoDB; HSC2_619_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1287
DR   PubChem_Cell_line; CVCL_1287
DR   RCB; RCB1945
DR   TKG; TKG 0487
DR   Wikidata; Q54076889
RX   PubMed=1570156;
RX   PubMed=2228902;
RX   PubMed=2585303;
RX   PubMed=9023415;
RX   PubMed=9290701;
RX   PubMed=10069537;
RX   PubMed=11416159;
RX   PubMed=11755821;
RX   PubMed=12738951;
RX   PubMed=17052259;
RX   PubMed=17325662;
RX   PubMed=17599052;
RX   PubMed=18097548;
RX   PubMed=18973137;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23992541;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32990596;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~38 hours (Note=Lot 012999), 27 hours (Note=Lot 07152004), 34 hours (Note=Lot 02172009), ~32 hours (Note=Lot 08082012), ~30 hours (Note=Lot 06192015), ~18 hours (Note=Lot 06192017), ~26 hours (Note=Lot 02082021) (JCRB=JCRB0622).
CC   HLA typing: A*24:02,33:02; B*44:03:01,54:01; C*01:02,14:03 (PubMed=9023415).
CC   HLA typing: A*24:02,33:03; B*08:01,54:01; C*01:02,14:03; DQA1*02:01,05:02; DQB1*06:08,06:08; DRB1*11:30,13:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=18097548).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=1570156).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.05%; Native American=0%; East Asian, North=83.8%; East Asian, South=14.71%; South Asian=1.36%; European, North=0%; European, South=0.07% (PubMed=30894373).
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; Genomics_Center_BCF_Technion; JCRB; PubMed=11416159; RCB; TKG
ST   Amelogenin: X (JCRB)
ST   Amelogenin: X,Y (Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=11416159; RCB; TKG)
ST   CSF1PO: 12,13
ST   D10S1248: 13
ST   D12S391: 18
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 19
ST   D19S433: 14
ST   D1S1656: 15,17,18
ST   D21S11: 31.2
ST   D22S1045: 15
ST   D2S1338: 19
ST   D2S441: 10
ST   D3S1358: 15,17
ST   D5S818: 10,12
ST   D7S820: 9,12
ST   D8S1179: 10,14
ST   DYS391: 10
ST   FGA: 19,21
ST   Penta D: 9
ST   Penta E: 12,15
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C4833; Oral cavity squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
//
RX   PubMed=2585303; DOI=10.1111/j.1600-0714.1989.tb01570.x;
RA   Momose F., Araida T., Negishi A., Ichijo H., Shioda S., Sasaki S.;
RT   "Variant sublines with different metastatic potentials selected in
RT   nude mice from human oral squamous cell carcinomas.";
RL   J. Oral Pathol. Med. 18:391-395(1989).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10069537; DOI=10.1111/j.1600-0714.1999.tb02006.x;
RA   Hoteiya T., Hayashi E., Satomura K., Kamata N., Nagayama M.;
RT   "Expression of E-cadherin in oral cancer cell lines and its
RT   relationship to invasiveness in SCID mice in vivo.";
RL   J. Oral Pathol. Med. 28:107-111(1999).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11755821; DOI=10.1016/S1368-8375(01)00022-7;
RA   Niinaka Y., Haga A., Negishi A., Yoshimasu H., Raz A., Amagasa T.;
RT   "Regulation of cell motility via high and low affinity autocrine
RT   motility factor (AMF) receptor in human oral squamous carcinoma
RT   cells.";
RL   Oral Oncol. 38:49-55(2002).
//
RX   PubMed=12738951; DOI=10.1067/moe.2003.36;
RA   Sugiyama M., Bhawal U.K., Dohmen T., Ono S., Miyauchi M., Ishikawa T.;
RT   "Detection of human papillomavirus-16 and HPV-18 DNA in normal,
RT   dysplastic, and malignant oral epithelium.";
RL   Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:594-600(2003).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x;
RA   Kozaki K.-i., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//
RX   PubMed=18973137; DOI=10.1002/gcc.20626;
RA   Sugimoto T., Seki N., Shimizu S., Kikkawa N., Tsukada J., Shimada H.,
RA   Sasaki K., Hanazawa T., Okamoto Y., Hata A.;
RT   "The galanin signaling cascade is a candidate pathway regulating
RT   oncogenesis in human squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 48:132-142(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23992541; DOI=10.1111/cas.12271;
RA   Chikamatsu K., Ishii H., Murata T., Sakakura K., Shino M., Toyoda M.,
RA   Takahashi K., Masuyama K.;
RT   "Alteration of cancer stem cell-like phenotype by histone deacetylase
RT   inhibitors in squamous cell carcinoma of the head and neck.";
RL   Cancer Sci. 104:1468-1475(2013).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32990596; DOI=10.7554/eLife.57761;
RA   Chai A.W.Y., Yee P.S., Price S., Yee S.M., Lee H.M., Tiong V.K.H.,
RA   Goncalves E., Behan F.M., Bateson J., Gilbert J.G.R., Tan A.-C.,
RA   McDermott U., Garnett M.J., Cheong S.-C.;
RT   "Genome-wide CRISPR screens of oral squamous cell carcinoma reveal
RT   fitness genes in the Hippo pathway.";
RL   eLife 9:e57761.1-e57761.34(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//